Autoimmune Disease

Category

Results from SOBI’S Pivotal Phase 2/3 Study of Emapalumab in Patients with Primary HLH Published in New England Journal of Medicine

SOBI announced that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary hemophagocytic lymphohistiocytosis (HLH) were published in the New England Journal of Medicine on 7 May 2020. Emapalumab is the...

Spanish Pediatric Anti-MOG Study Group Discovery Could Accelerate Diagnosis & Treatment of Children with Life-Threatening Neurological Diseases

In observational research, a multi-center team of investigators called the “Spanish Pediatric Anti-MOG Study Group” discovered that 85% of children in a study with life-threatening autoimmune conditions had complete or near complete recovery after a specific biomarker...

Orchard Therapeutics Granted FDA Orphan Drug Designation for OTL-102 for X-linked Chronic Granulomatous Disease (X-CGD)

Orchard Therapeutics announced the U.S. FDA has granted Orphan Drug Designation for OTL-102, the company’s ex vivo autologous hematopoietic stem cell (HSC) gene therapy being investigated for the treatment of X-linked chronic granulomatous disease (X-CGD). The FDA may...

Pin It on Pinterest